Here, we describe two insights into the role of receptor conformational dynamics during agonist release (all-trans retinal, ATR) from the visual G protein-coupled receptor (GPCR) rhodopsin. First, we show that, after light activation, ATR can continually release and rebind to any receptor remaining in an active-like conformation. As with other GPCRs, we observe that this equilibrium can be shifted by either promoting the active-like population or increasing the agonist concentration. Second, we find that during decay of the signaling state an active-like, yet empty, receptor conformation can transiently persist after retinal release, before the receptor ultimately collapses into an inactive conformation. The latter conclusion is based on time-resolved, site-directed fluorescence labeling experiments that show a small, but reproducible, lag between the retinal leaving the protein and return of transmembrane helix 6 (TM6) to the inactive conformation, as determined from tryptophan-induced quenching studies. Accelerating Schiff base hydrolysis and subsequent ATR dissociation, either by addition of hydroxylamine or introduction of mutations, further increased the time lag between ATR release and TM6 movement. These observations show that rhodopsin can bind its agonist in equilibrium like a traditional GPCR, provide evidence that an active GPCR conformation can persist even after agonist release, and raise the possibility of targeting this key photoreceptor protein by traditional pharmaceutical-based treatments.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081659 | PMC |
http://dx.doi.org/10.1073/pnas.1606347113 | DOI Listing |
Background: Aggregation of the hyperphosphorylated tau protein in neurofibrillary tangles (NFTs) is a pathological hallmark of Alzheimer's Disease (AD). Several kinases contribute to the pathological phosphorylation of tau (pTau). However, kinase-targeted therapies for AD have failed in clinical trials due to largely unknown mechanism of action, low efficacy, and severe side-effects.
View Article and Find Full Text PDFBackground: G protein-coupled receptors (GPCRs) are associated with multiple stages of the pathophysiology of Alzheimer's disease (AD). Biased GPCR signaling preferentially activates G protein- or β-arrestin-mediated signaling pathways and presents opportunities to develop more selective and safer therapeutics but remains largely unexplored in AD. Recently, we developed a G protein-biased GPR3 AD mouse model, which does not recruit β-arrestin 2, that displays reduced amyloid-β (Aβ) pathology without adverse cognitive effects associated with elimination of both G protein and β-arrestin signaling.
View Article and Find Full Text PDFBackground: Alzheimer's Disease (AD) is neuropathologically characterized by the accumulation of Amyloid-β (Aβ) plaques, neurofibrillary tangles, and neuroinflammation. GPR3 is a G protein-coupled receptor (GPCR) that has been implicated in Aβ pathogenesis via β-arrestin 2 (βarr2)-mediated intracellular signaling. Genetic deletion of Gpr3 reduces the Aβ plaque burden and cognitive decline in AD transgenic mice.
View Article and Find Full Text PDFSheng Li Xue Bao
December 2024
Skin Disease Research Institute, the Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou 310058, China.
Skin, as the body's largest organ, acts as the primary defense mechanism against infection and injury. The maintenance of skin health heavily relies on the regulation of epidermal stem cells, crucial for ensuring epidermal homeostasis, hair regeneration, and the repair of epidermal injuries. Recent studies have placed a growing emphasis on G protein-coupled receptor (GPCR) in the context of understanding epidermal stem cells, uncovering its significant role in determining their fate.
View Article and Find Full Text PDFNat Chem Biol
January 2025
The Bridge Institute, Michelson Center for Convergent Biosciences, University of Southern California, Los Angeles, CA, USA.
Opioid receptors, a subfamily of G protein-coupled receptors (GPCRs), are key therapeutic targets. In the canonical GPCR activation model, agonist binding is required for receptor-G protein complex formation, while antagonists prevent G protein coupling. However, many GPCRs exhibit basal activity, allowing G protein association without an agonist.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!